Henlius Biotech braves political turmoil with $477m IPO
Shanghai Henlius Biotech launched a Hong Kong SAR listing on Wednesday, becoming the first issuer to test the market after earnings season and while protests continue to rip through the city.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: